The nonprofit, which is focused on advancing the cannabis industry, joins a network of industry experts from over a hundred different organizations.
In a press release (1) dated May 1, 2024, the S3 Collective, a nonprofit with the mission of “advancing the cannabis industry through collaboration, education, and standardization,” announced its acceptance into the Food and Drug Administration’s (FDA) Network of Experts (NoE) program.
“Recently, we achieved one of our milestones,” stated David Vaillencourt in a May 23, 2024, LinkedIn post regarding the announcement (2). “The FDA officially accepted our non profit into their Network of Experts program. As the 132nd organization to be accepted, I am honored to be able to provide the agency with knowledge and resources it may need on all topics of cannabinoids and psychedelics. Life is about the journey not the destination, and this is but one important step towards a future where minimum standards ensure that all products containing cannabinoids have a level of safety and quality that patients deserve.”
Vaillencourt recently participated in a panel discussion, “Federal Rescheduling: Opinions and Impacts,” at the Cannabis Science Conference in Kansas City, Missouri, which provided a range of expert opinions on the recent potential rescheduling of cannabis to a Schedule III drug.
According to the FDA (3), the NoE origins began in 2012 and the program has continued to grow as “a vetted network of partner organizations and their member scientists, clinicians and engineers who can provide the FDA rapid access to expertise when it is needed to supplement existing knowledge and expertise within the Center for Devices and Radiological Health (CDRH) and the Center for Drug Evaluation and Research (CDER).” The S3 news release added, “S3 Collective is the 132nd nonprofit organization and the first cannabis-related nonprofit to participate in this initiative.”
The FDA lists the following as requirements for an organization to be a part of the NoE (3):
“S3 Collective is uniquely positioned to contribute to the NoE program as they engage a diverse array of scientists and technical experts that champion data-driven standards for consumer protection and contribute impartial information and data to the cannabis and hemp industries,” the S3 news release stated (1). “When a need arises, S3 Collective looks forward to connecting their technical experts with the FDA to give evidence-based insights on specific topics.”
The S3 Collective was founded in 2023 by David Vaillencourt, Vice-Chair of ASTM Committee D37 on Cannabis and founder of the GMP Collective, and Alexa Wilson, Director of the Design+Build Division at Omega Equipment & Supply (4). In January of this year, the S3 Collective held a webinar, “Rescheduling Cannabis: A Scientific Imperative,” which provided an explanation of the proposed scheduling, how and why to contribute to the federal framework of cannabis regulations, and the S3 Collective's anticipated approach, with the overall goal of creating a science-based submission to the DEA’s public comment period.
References
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part II
December 17th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election, including state and federal policies and possible paths forward for testing standardization. Join us in the second part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Cannabis, US Presidential Election 2024, and Beyond: A Roundtable Discussion, Part I
December 16th 2024With the recent 2024 presidential election behind us, the future of cannabis still has many unknowns moving forward and questions still to be discussed. In this roundtable discussion with four knowledgeable industry leaders, we explore the nuanced political landscape of cannabis legalization and rescheduling in the context of the election. We discuss what drives support or opposition from both sides of the aisle, the complexities of balancing state and federal priorities, and more. Join us in the first part of a compilation of responses from Kim Anzarut, CQA, CP-FS, CEO of Allay Consulting; Susan Audino, PhD, founder of S.A. Audino & Associates, LLC; Zacariah Hildenbrand, PhD, research Professor at the University of Texas at El Paso; and David Vaillencourt, CEO of The GMP Collective.
Work Smarter, Not Harder: How ASTM Standards for Cannabinoids Improve Your Operations
December 3rd 2024ASTM Standards D8557-24 and D8556-24, provide unified guidelines for GMP (Good Manufacturing Practices) and QMS (Quality Management Systems) in cannabis operations. These standards enhance compliance, product safety, and operational consistency across the industry for the benefit of operators, consumers, and other stakeholders in the industry.